New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
dc.contributor.author | Jarosinski, Mark A. | |
dc.contributor.author | Chen, Yen-Shan | |
dc.contributor.author | Varas, Nicolás | |
dc.contributor.author | Dhayalan, Balamurugan | |
dc.contributor.author | Chatterjee, Deepak | |
dc.contributor.author | Weiss, Michael A. | |
dc.contributor.department | Biochemistry and Molecular Biology, School of Medicine | |
dc.date.accessioned | 2023-09-26T13:39:38Z | |
dc.date.available | 2023-09-26T13:39:38Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Design of “first-generation” insulin analogues over the past 3 decades has provided pharmaceutical formulations with tailored pharmacokinetic (PK) and pharmacodynamic (PD) properties. Application of a molecular tool kit—integrating protein sequence, chemical modification, and formulation—has thus led to improved prandial and basal formulations for the treatment of diabetes mellitus. Although PK/PD changes were modest in relation to prior formulations of human and animal insulins, significant clinical advantages in efficacy (mean glycemia) and safety (rates of hypoglycemia) were obtained. Continuing innovation is providing further improvements to achieve ultrarapid and ultrabasal analogue formulations in an effort to reduce glycemic variability and optimize time in range. Beyond such PK/PD metrics, next-generation insulin analogues seek to exploit therapeutic mechanisms: glucose-responsive (“smart”) analogues, pathway-specific (“biased”) analogues, and organ-targeted analogues. Smart insulin analogues and delivery systems promise to mitigate hypoglycemic risk, a critical barrier to glycemic control, whereas biased and organ-targeted insulin analogues may better recapitulate physiologic hormonal regulation. In each therapeutic class considerations of cost and stability will affect use and global distribution. This review highlights structural principles underlying next-generation design efforts, their respective biological rationale, and potential clinical applications. | |
dc.identifier.citation | Jarosinski MA, Chen YS, Varas N, Dhayalan B, Chatterjee D, Weiss MA. New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals. J Clin Endocrinol Metab. 2022;107(4):909-928. doi:10.1210/clinem/dgab849 | |
dc.identifier.uri | https://hdl.handle.net/1805/35793 | |
dc.language.iso | en_US | |
dc.publisher | The Endocrine Society | |
dc.relation.isversionof | 10.1210/clinem/dgab849 | |
dc.relation.journal | The Journal of Clinical Endocrinology & Metabolism | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Protein engineering | |
dc.subject | Protein design | |
dc.subject | Insulin action | |
dc.subject | Insulin signaling | |
dc.subject | Molecular pharmacology | |
dc.title | New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals | |
dc.type | Article | |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947325/ |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- New Horizons Next-Generation Insulin Analogues Structural Principles.pdf
- Size:
- 968.99 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: